Literature DB >> 23542683

Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.

Nidhi Gupta1, Zhihua Xu, Ahmed El-Sehemy, Helen Steed, Yangxin Fu.   

Abstract

OBJECTIVE: Notch3 is implicated in chemoresistance of ovarian cancer, yet the molecular mechanism underlying Notch3-mediated drug resistance remains to be elucidated. Here, we investigated the role of Notch3 in carboplatin-induced apoptosis in ovarian cancer cells.
METHODS: Ovarian cancer cell line OVCA429 cells were stably transduced with an empty vector or a retroviral vector expressing the Notch3 intracellular domain (NICD3, the constitutively active form of Notch3) to generate OVCA429/vector and OVCA429/NICD3 cells. Epithelial-mesenchymal transition (EMT) was determined by morphological change and expression of the EMT markers. Carboplatin-induced cytotoxicity was determined by the neutral red uptake assay. Apoptosis was determined by Annexin V staining and Western blotting. Carboplatin-induced phosphorylation of extracellular signal-regulated kinase (ERK) was identified by a phospho-kinase array and confirmed by Western blotting.
RESULTS: Activation of Notch3 in OVCA429 cells causes a spindle and fibroblast-like morphology, induces the expression of smooth muscle α-actin, Slug and Snail, but decreases the expression of E-cadherin, indicating that Notch3 activation induces EMT in OVCA429 cells. Furthermore, Notch3 activation renders OVCA429 cells more resistant to carboplatin-induced cytotoxicity and attenuates carboplatin-induced apoptosis in these cells. Our results indicate that phosphorylation of ERK is a positive regulator of carboplatin-induced apoptosis in OVCA429 cells. Interestingly, carboplatin-induced ERK phosphorylation is inhibited by Notch3 activation.
CONCLUSIONS: Notch3 activation induces EMT and attenuates carboplatin-induced apoptosis in OVCA429 cells. ERK phosphorylation plays a pro-apoptotic role in carboplatin-induced apoptosis in OVCA429 cells. Interestingly, Notch3 activation attenuates carboplatin-induced ERK phosphorylation in these cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23542683     DOI: 10.1016/j.ygyno.2013.03.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  32 in total

Review 1.  The Role of Notch3 in Cancer.

Authors:  Zviadi Aburjania; Samuel Jang; Jason Whitt; Renata Jaskula-Stzul; Herbert Chen; J Bart Rose
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 3.  Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance.

Authors:  Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose
Journal:  Oncologist       Date:  2021-01-02

Review 4.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

5.  MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.

Authors:  Fei Guo; David Cogdell; Limei Hu; Da Yang; Anil K Sood; Fengxia Xue; Wei Zhang
Journal:  Oncol Rep       Date:  2014-03-21       Impact factor: 3.906

Review 6.  Notch signaling in serous ovarian cancer.

Authors:  Jolijn W Groeneweg; Rosemary Foster; Whitfield B Growdon; René H M Verheijen; Bo R Rueda
Journal:  J Ovarian Res       Date:  2014-11-04       Impact factor: 4.234

7.  Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Authors:  Corine M Beaufort; Jean C A Helmijr; Anna M Piskorz; Marlous Hoogstraat; Kirsten Ruigrok-Ritstier; Nicolle Besselink; Muhammed Murtaza; Wilfred F J van IJcken; Anouk A J Heine; Marcel Smid; Marco J Koudijs; James D Brenton; Els M J J Berns; Jozien Helleman
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

8.  Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin.

Authors:  Tiffany J Tzeng; Lei Cao; YangXin Fu; Huawei Zeng; Wen-Hsing Cheng
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

9.  Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.

Authors:  Jolijn W Groeneweg; Celeste M DiGloria; Jing Yuan; William S Richardson; Whitfield B Growdon; Sriram Sathyanarayanan; Rosemary Foster; Bo R Rueda
Journal:  Front Oncol       Date:  2014-07-07       Impact factor: 6.244

10.  HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Authors:  Andrew E Teschendorff; Shih-Han Lee; Allison Jones; Heidi Fiegl; Marie Kalwa; Wolfgang Wagner; Kantaraja Chindera; Iona Evans; Louis Dubeau; Arturo Orjalo; Hugo M Horlings; Lukas Niederreiter; Arthur Kaser; Winnie Yang; Ellen L Goode; Brooke L Fridley; Richard G Jenner; Els M J J Berns; Elisabeth Wik; Helga B Salvesen; G Bea A Wisman; Ate G J van der Zee; Ben Davidson; Claes G Trope; Sandrina Lambrechts; Ignace Vergote; Hilary Calvert; Ian J Jacobs; Martin Widschwendter
Journal:  Genome Med       Date:  2015-10-24       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.